PMID- 27516726
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160812
LR  - 20220311
IS  - 1357-714X (Print)
IS  - 1369-1643 (Electronic)
IS  - 1357-714X (Linking)
VI  - 2016
DP  - 2016
TI  - A Systematic Literature Review of Adverse Events Associated with Systemic 
      Treatments Used in Advanced Soft Tissue Sarcoma.
PG  - 3597609
LID - 10.1155/2016/3597609 [doi]
LID - 3597609
AB  - This systematic literature review describes adverse events (AEs) among patients 
      with soft tissue sarcoma (STS) who received second-line or later anticancer 
      therapies. Searches were conducted in PubMed, EMBASE, and Cochrane Central 
      Register of Controlled Trials for studies of adults with advanced or metastatic 
      STS who received systemic anticancer therapy before enrollment in a 
      randomized-controlled trial of pazopanib, another targeted cancer agent, or 
      cytotoxic chemotherapy. Of 204 publications identified, seven articles 
      representing six unique studies met inclusion criteria. Additional safety results 
      for pazopanib were identified on ClinicalTrials.gov. Hematologic toxicities were 
      common with all therapies evaluated (pazopanib, trabectedin, dacarbazine +/- 
      gemcitabine, gemcitabine +/- docetaxel, cyclophosphamide, and ifosfamide). Studies 
      differed in AE type, timing of assessment, and outcomes reported, although 
      patient populations and AE assessment timing were relatively similar for 
      pazopanib and trabectedin. AEs that were more common with trabectedin than 
      pazopanib were anemia, neutropenia, nausea/vomiting, and elevations in aspartate 
      aminotransferase and alanine aminotransferase. An AE that was more common with 
      pazopanib than trabectedin was anorexia. Only the pazopanib study reported AE 
      frequencies versus placebo. A planned meta-analysis was not feasible, as there 
      was no common comparator. More well-designed studies that include common 
      comparators are needed for comparison of safety effects among treatments for STS.
FAU - Colosia, Ann
AU  - Colosia A
AUID- ORCID: 0000-0003-4164-7524
AD  - Market Access and Outcomes Strategy, RTI Health Solutions, 200 Park Offices 
      Drive, Research Triangle Park, Durham, NC 27709, USA.
FAU - Khan, Shahnaz
AU  - Khan S
AD  - Market Access and Outcomes Strategy, RTI Health Solutions, 200 Park Offices 
      Drive, Research Triangle Park, Durham, NC 27709, USA.
FAU - Hackshaw, Michelle D
AU  - Hackshaw MD
AD  - US Health Outcomes, Oncology, GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 
      19112, USA.
FAU - Oglesby, Alan
AU  - Oglesby A
AD  - US Health Outcomes, Oncology, GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 
      19112, USA.
FAU - Kaye, James A
AU  - Kaye JA
AD  - Epidemiology, RTI Health Solutions, 1440 Main Street, Suite 310, Waltham, MA 
      02451, USA.
FAU - Skolnik, Jeffrey M
AU  - Skolnik JM
AD  - US Medical Affairs, Oncology, GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 
      19112, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160719
PL  - Egypt
TA  - Sarcoma
JT  - Sarcoma
JID - 9709257
PMC - PMC4969544
EDAT- 2016/08/16 06:00
MHDA- 2016/08/16 06:01
PMCR- 2016/07/19
CRDT- 2016/08/13 06:00
PHST- 2016/02/01 00:00 [received]
PHST- 2016/06/06 00:00 [accepted]
PHST- 2016/08/13 06:00 [entrez]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2016/08/16 06:01 [medline]
PHST- 2016/07/19 00:00 [pmc-release]
AID - 10.1155/2016/3597609 [doi]
PST - ppublish
SO  - Sarcoma. 2016;2016:3597609. doi: 10.1155/2016/3597609. Epub 2016 Jul 19.